Targeted Therapy in Advanced Gastric Cancer: An Updated Review
Journal Title: Journal of Cancer Sciences - Year 2014, Vol 1, Issue 1
Abstract
Despite great efforts over the years, adenocarcinoma of the stomach remains a difficult disease to manage. It is the second leading cause of cancer death and is the fifth most common cancer worldwide. If diagnosed early, surgical resection can offer definitive therapy. However, disease is often advanced or metastatic at the time of diagnosis and chemotherapy becomes the only option. With increased understanding of the molecular pathways that are responsible for tumor development and proliferation, targeted therapies have become an important part of cancer treatment in the setting of advanced or metastatic disease. Trastuzumab is widely used in HER2-positive breast cancer. Similarly, the ToGA trial established its role in gastric cancer that overexpresses HER2 by demonstrating an overall survival benefit in that cohort. Based on these results, HER2 testing should be performed routinely in patients with metastatic gastric cancer in order to identify patients who can benefit from this biologic agent. Ramucirumab also improves survival either as a single agent or when combined with chemotherapy after disease progression using standard first-line therapy. Unfortunately, these favorable responses are not seen with many other targeted agents in gastric cancer. This review aims to outline and summarize currently available knowledge and clinical data for some of the most common signaling targets and their respective therapeutic trials.
Authors and Affiliations
Lakshmi Rajdev
Keywords
Related Articles
- EP ID EP207001
- DOI 10.13188/2377-9292.1000003
- Views 138
- Downloads 0
Rectifying the Epigenetic Field Defect in Gastric Carcinogenesis
Gastric cancer is undoubtedly a fatal malignancy worldwide with high incidence and dismal prognosis. Its formation and development can be driven by genetic defects, dietary factors, alcohol consumption, viral infection,...
Targeting Pancreatic Cancer Stem Cells
Carcinomas of an epithelial-origin account for the majority of all malignant cancers worldwide. As the most common pancreatic cancer, Pancreatic Ductal Adeno Carcinoma (PDAC) is a carcinoma with an extremely high lethali...
Gemcitabine-Capecitabine Chemotherapy Plus Intra- Arterial Epirubicin-Cisplatin in Pancreatic Cancer Patients after FOLFIRINOX First Line Chemotherapy: A Retrospective Analysis
Background: Most pancreatic cancer patients have disease recurrence/progression within 6 months from firstline chemotherapy end. Today, there is no a standard of care of second-line therapy. Materials (patients) and me...
Constitutive Developmental Modeling of Genomic Integrityand Epigenetic Interactivity in Neuroblastoma
The essential formulas of possible progression or non-progression are dimensionally and potentially highly divergent systems of operative aggressive growth and spread of a neuroblastoma. As such, an essential integrity o...
White Adipose Tissue Browning and Cancer Cachexia
Cachexia or wasting syndrome is often seen in cancer patients. Over half of the patients suffer from this condition although the incidence varies from tumor types. Symptoms of cancer cachexia include progressive weight l...